FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study (original) (raw)

References

• Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A (2014) Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer 17 (1): 34–42.
  Article CAS PubMed Google Scholar
• Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15: 441–451.
  Article CAS PubMed Google Scholar
• Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z (2010) GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 70: 7630–7639.
  Article CAS PubMed Google Scholar
• Bang YJ (2012) Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 46: 637–648.
  Article CAS PubMed Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.
  Article CAS PubMed Google Scholar
• Brooks AN, Kilgour E, Smith PD (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18: 1855–1862.
  Article CAS PubMed Google Scholar
• Cunningham D, Oliveira J (2008) Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 (Suppl 2): ii23–ii24.
  PubMed Google Scholar
• Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O’Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591–7595.
  Article CAS PubMed Google Scholar
• Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673–684.
  Article CAS PubMed Google Scholar
• Dulak AM, Schumacher SE, van LJ, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, Lin L, Bandla S, Luketich JD, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72: 4383–4393.
  Article CAS PubMed PubMed Central Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139–149.
  Article CAS PubMed Google Scholar
• Fukumoto S (2008) Actions and mode of actions of FGF19 subfamily members. Endocr J 55: 23–31.
  Article CAS PubMed Google Scholar
• Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72: 2045–2056.
  Article CAS PubMed Google Scholar
• GLOBOCAN statistics 2008. Available at http://globocan.iarc.fr/ (2009) Fluorescence In Situ Hybridization (FISH) Application Guide. Springer.
• Grose R, Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16: 179–186.
  Article CAS PubMed Google Scholar
• Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brummendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus Porta D (2012) FGFR genetic alterations predict for sensitivity to NVP-BGJ398,a selective pan-FGFR inhibitor. Cancer Discov 2: 1118–1133.
  Article CAS PubMed Google Scholar
• Hamilton SR, Aaltonen LA (2000) World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System. IARC Press: Lyon. 38–52.
  Google Scholar
• Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78: 1143–1153.
  CAS PubMed Google Scholar
• Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2: 1373–1381.
  CAS PubMed Google Scholar
• Jang JH, Shin KH, Park JG (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61: 3541–3543.
  CAS PubMed Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
  Article PubMed Google Scholar
• Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH (2012) Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 43: 1559–1566.
  Article CAS PubMed Google Scholar
• Kang H, Kauh JS (2011) Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol 12: 96–106.
  Article PubMed Google Scholar
• Kaplan EL, Meier P (1958) Nonparametric-estimation from incomplete observations. Amer Statistical Assoc 53: 457–481.
  Article Google Scholar
• Katoh M (2010) Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther 10: 1375–1379.
  Article CAS PubMed Google Scholar
• Katoh M, Katoh M (2006) FGF signaling network in the gastrointestinal tract (review). Int J Oncol 29: 163–168.
  CAS PubMed Google Scholar
• Lauren P (1965) The two histological main types of gastriccarcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31–49.
  Article CAS PubMed Google Scholar
• Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Goette H, Melezinkova H, Moehler M (2013) Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: Randomized controlled phase III EXPAND study. Lancet Oncol 14: 490–499.
  Article CAS PubMed Google Scholar
• Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y (2012) FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106: 727–732.
  Article CAS PubMed PubMed Central Google Scholar
• Mor O, Ranzani GN, Ravia Y, Rotman G, Gutman M, Manor A, Amadori D, Houldsworth J, Hollstein M, Schwab M, Shiloh Y (1993) DNA amplification in human gastric carcinomas. Cancer Genet Cytogenet 65: 111–114.
  Article CAS PubMed Google Scholar
• Nadauld L, Regan JF, Miotke L, Pai RK, Longacre TA, Kwok SS, Saxonov S, Ford JM, Ji HP (2012) Quantitative and sensitive detection of cancer genome amplifications from formalin fixed paraffin embedded tumors with droplet digital pcr. Transl Med (Sunnyvale) 2: pii: 1000107.
  Article Google Scholar
• Nakatani H, Sakamoto H, Yoshida T, Yokota J, Tahara E, Sugimura T, Terada M (1990) Isolation of an amplified DNA sequence in stomach cancer. Jpn J Cancer Res 81: 707–710.
  Article CAS PubMed PubMed Central Google Scholar
• Narita T, Seshimo A, Suzuki M, Murata J, Kameoka S (2013) Status of Tissue Expression and Serum Levels of HER2 in Gastric Cancer Patients in Japan. Hepatogastroenterology 60: 1083–1088.
  PubMed Google Scholar
• Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, Tompkins D, Axon A (2006) Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 55: 1545–1552.
  Article CAS PubMed PubMed Central Google Scholar
• Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, Stenning S (2012) Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 24: 1253–1261.
  Article PubMed Google Scholar
• Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours 6th edn. Wiley-Liss: New York.
  Google Scholar
• Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, O'Meara S, Parker A, Tarpey P, Avis T, Barthorpe A, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Yuen ST, Nicholson AG, Lakhani S, Easton DF, Weber BL, Stratton MR, Futreal PA, Wooster R (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: 590–592.
  Article CAS PubMed Google Scholar
• Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M (2012) Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18: 5992–6000.
  Article CAS PubMed Google Scholar
• Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116–129.
  Article CAS PubMed Google Scholar
• Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van KM, Kreike B, Mackay A, Ashworth A, van d V, Reis-Filho JS (2010a) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013–2023.
  Article CAS PubMed PubMed Central Google Scholar
• Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010b) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085–2094.
  Article CAS PubMed PubMed Central Google Scholar
• Van Cutsem E, De HS, Kang YK, Ohtsu A, Tebbutt NC, Ming XJ, Peng YW, Langer B, Delmar P, Scherer SJ, Shah MA (2012a) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30: 2119–2127.
  Article CAS PubMed Google Scholar
• Van Cutsem E, Yeh K-H, Bang YJ, Shen L, Ajani JA, Bai Y-X, Chung HC, Pan H-M, Chin K, Muro K, Kim YH, Smith H, Costantini C, Musalli S, Rizvi S, Sahmoud T, Ohtsu A (2012b) Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 30 (15S): abst LBA3.
  Article Google Scholar
• Varella-Garcia M (2006) Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1: 19.
  Article PubMed PubMed Central Google Scholar
• Waddell T, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Okines A, Cunningham D (2012) A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 30 (15S): abst LBA4000 Ref Type: Abstract.
  Article Google Scholar
• Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, Rocken C (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24: 725–733.
  Article CAS PubMed Google Scholar
• Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansen S, Rauh D, Baessmann I, Altmuller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas RK (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2: 62ra93.
  Article CAS PubMed PubMed Central Google Scholar
• Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang LH, Ji JF, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19: 2572–2583.
  Article CAS PubMed Google Scholar
• Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR (2012) Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 18: 6658–6667.
  Article CAS PubMed Google Scholar
• Zhao WM, Wang L, Park H, Chhim S, Tanphanich M, Yashiro M, Kim KJ (2010) Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res 16: 5750–5758.
  Article CAS PubMed PubMed Central Google Scholar

Download references